Puma Biotechnology (PBYI) Q3 2026 Earnings Call Transcript
Puma Biotechnology (PBYI) reported Q3 2026 revenue of $55.1M, up from Q2 2026. NERLYNX sales accounted for $54.1M, with 2,818 bottles sold. Royalty revenue was $0.9M. The company discussed ongoing phase II trials for alisertib in lung and breast cancer, with updated data expected at the San Antonio Breast Cancer Symposium in December 2026.
How this was made
The 30-second read
Why it matters
The transcript combines a fresh quarterly financial snapshot with a concrete clinical-trial protocol change for ALISCA-Breast1 (continuing enrollment only in 40 mg and 50 mg groups) and a stated catalyst for updated interim data at the San Antonio Breast Cancer Symposium in December.
Market read
Traders can use the Q3 revenue detail and the ALISCA-Breast1 amendment plus December data timing to reassess near-term probability-weighted outcomes and risk for PBYI.
What to watch
Key decision points are not fully quantified here, including magnitude of biomarker activity, updated enrollment pace, and any explicit cash runway or guidance, which can dominate near-term valuation.
Background
Puma Biotechnology held its Q3 2026 earnings call on Nov. 5, 2026, discussing NERLYNX commercial results and ongoing Phase II alisertib trials (ALISCA-Breast1, ALISCA-Lung1, ALISCA-Lung2).
Ticker impact
Puma reports Q3 2026 revenue of $55.1M and updates ALISCA-Breast1 dosing, with amended enrollment and planned December interim data.
Likely mixed reaction, with support from revenue detail and trial momentum, offset by uncertainty around prescription trends and the implications of amended dosing.
The transcript provides concrete Q3 financial figures and a specific trial amendment (40 mg and 50 mg only) plus a December data timeline, but it does not include Phase 3 outcomes or guidance beyond the call narrative.
Market effects
Biotech investors may reprice small-cap oncology trial probability and NERLYNX commercial trajectory based on updated ALISCA-Breast1 enrollment and upcoming SABCS interim data.
Limited direct regional spillover; primarily affects US-listed small-cap biotech sentiment.
Modest global relevance via international regulatory engagement plans for a potential Phase 3 design in 1H 2027.
Counterpoint
The revenue and prescription commentary could reflect demand softness, and the ALISCA-Breast1 amendment may signal earlier signals were not strong enough to justify all dose groups.
Key entities
- companyPuma Biotechnology
Subject of the earnings call transcript, reporting Q3 2026 results and trial updates for alisertib and NERLYNX.
- productNERLYNX
Puma’s commercial drug; Q3 2026 product revenue net is described as consisting entirely of NERLYNX sales and related royalties.
- clinical_trialALISCA-Breast1
Phase II alisertib plus endocrine therapy trial in HER2-negative, hormone receptor-positive breast cancer; amended to continue enrollment only in 40 mg and 50 mg dose groups.
- eventSan Antonio Breast Cancer Symposium
December conference where Puma expects updated interim data from ALISCA-Breast1.
